Hashimoto K, Wun T C, Baird J, Lazarus G S, Jensen P J
Department of Dermatology, University of Pennsylvania, Philadelphia 19104.
J Invest Dermatol. 1989 Mar;92(3):310-4. doi: 10.1111/1523-1747.ep12277087.
To investigate the mechanisms by which cutaneous plasminogen activator (PA) may be regulated, we have tested cultured keratinocytes for the presence of PA inhibitors. Using biosynthetic labeling experiments with 35S-methionine in conjunction with specific antibody precipitation, we have shown that human keratinocytes in culture synthesized and secreted both PA inhibitor 1 and PA inhibitor 2. PA inhibitor 1 was present in conditioned media in the inactive form, but it could be detected with reverse phase autography. PA inhibitor 2 was detected by its ability to form complexes with 125I-uPA. Potential therapeutic relevance for cutaneous PA inhibitor 2 was suggested in skin organ culture experiments which demonstrated that purified PA inhibitor 2 from human placenta was able to prevent the acantholytic changes induced by pemphigus IgG.
为了研究皮肤纤溶酶原激活剂(PA)可能的调节机制,我们检测了培养的角质形成细胞中PA抑制剂的存在情况。通过使用35S-甲硫氨酸进行生物合成标记实验并结合特异性抗体沉淀,我们发现培养的人角质形成细胞合成并分泌了PA抑制剂1和PA抑制剂2。PA抑制剂1以无活性形式存在于条件培养基中,但可通过反相自显影检测到。PA抑制剂2通过其与125I-uPA形成复合物的能力来检测。皮肤器官培养实验表明,从人胎盘中纯化的PA抑制剂2能够预防天疱疮IgG诱导的棘层松解变化,这提示了皮肤PA抑制剂2潜在的治疗意义。